Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients.

Hofman V, Rouquette I, Long-Mira E, Piton N, Chamorey E, Heeke S, Vignaud JM, Yguel C, Mazières J, Lepage AL, Bibeau F, Begueret H, Lassalle S, Lalvée S, Zahaf K, Benzaquen J, Poudenx M, Marquette CH, Sabourin JC, Ilié M, Hofman P.

J Thorac Oncol. 2019 Apr 15. pii: S1556-0864(19)30283-7. doi: 10.1016/j.jtho.2019.03.024. [Epub ahead of print]

PMID:
30999109
2.

The Long Non-Coding RNA DNM3OS is a Reservoir of FibromiRs with Major Functions in Lung Fibroblast Response to TGF-β and Pulmonary Fibrosis.

Savary G, Dewaeles E, Diazzi S, Buscot M, Nottet N, Fassy J, Courcot E, Henaoui IS, Lemaire J, Martis N, Van der Hauwaert C, Pons N, Magnone V, Leroy S, Hofman V, Plantier L, Lebrigand K, Paquet A, Lino Cardenas CL, Vassaux G, Hofman P, Günther A, Crestani B, Wallaert B, Rezzonico R, Brousseau T, Glowacki F, Bellusci S, Perrais M, Broly F, Barbry P, Marquette CH, Cauffiez C, Mari B, Pottier N.

Am J Respir Crit Care Med. 2019 Apr 9. doi: 10.1164/rccm.201807-1237OC. [Epub ahead of print]

PMID:
30964696
3.

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.

Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, de Koning L, Copin MC, Hofman P, Hofman V, Porte H, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, de Reyniès A, Jean D.

Nat Commun. 2019 Mar 22;10(1):1333. doi: 10.1038/s41467-019-09307-6.

4.

Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time?

Hofman P, Badoual C, Henderson F, Berland L, Hamila M, Long-Mira E, Lassalle S, Roussel H, Hofman V, Tartour E, Ilié M.

Cancers (Basel). 2019 Feb 27;11(3). pii: E283. doi: 10.3390/cancers11030283. Review.

5.

Circulating Tumor Cell Detection in Lung Cancer: But to What End?

Hofman V, Heeke S, Marquette CH, Ilié M, Hofman P.

Cancers (Basel). 2019 Feb 23;11(2). pii: E262. doi: 10.3390/cancers11020262. Review.

6.

Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.

Lantuejoul S, Damotte D, Hofman V, Adam J.

J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101. doi: 10.21037/jtd.2018.12.103. Review.

7.

Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.

Berland L, Heeke S, Humbert O, Macocco A, Long-Mira E, Lassalle S, Lespinet-Fabre V, Lalvée S, Bordone O, Cohen C, Leroy S, Hofman V, Hofman P, Ilié M.

J Thorac Dis. 2019 Jan;11(Suppl 1):S71-S80. doi: 10.21037/jtd.2018.11.102. Review.

8.

Resistances to EGFR tyrosine kinase inhibitors in lung cancer-how to routinely track them in a molecular pathology laboratory?

Hofman V, Hofman P.

J Thorac Dis. 2019 Jan;11(Suppl 1):S65-S70. doi: 10.21037/jtd.2018.11.76. Review.

9.

[The age of artificial intelligence in lung cancer pathology: Between hope, gloom and perspectives].

Heeke S, Delingette H, Fanjat Y, Long-Mira E, Lassalle S, Hofman V, Benzaquen J, Marquette CH, Hofman P, Ilié M.

Ann Pathol. 2019 Apr;39(2):130-136. doi: 10.1016/j.annpat.2019.01.003. Epub 2019 Feb 13. French.

PMID:
30772062
10.

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients.

Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudié H, Tanga V, Allégra M, Lespinet-Fabre V, Bordone O, Bonnetaud C, Schiappa R, Butori C, Bence C, Lacour JP, Hofman V, Hofman P.

Oncotarget. 2018 Nov 16;9(90):36238-36249. doi: 10.18632/oncotarget.26343. eCollection 2018 Nov 16.

11.

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.

Ilié M, Ngo-Mai M, Long-Mira E, Lassalle S, Butori C, Bence C, Hamila M, Hofman V, Hofman P.

J Vis Exp. 2018 Sep 25;(139). doi: 10.3791/58082.

PMID:
30320751
12.

Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.

Ilie M, Beaulande M, Hamila M, Erb G, Hofman V, Hofman P.

Lung Cancer. 2018 Oct;124:90-94. doi: 10.1016/j.lungcan.2018.07.037. Epub 2018 Jul 31.

PMID:
30268486
13.

Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma.

Ilié M, Beaulande M, Ben Hadj S, Chamorey E, Schiappa R, Long-Mira E, Lassalle S, Butori C, Cohen C, Leroy S, Guérin O, Mouroux J, Marquette CH, Pomerol JF, Erb G, Hofman V, Hofman P.

Cancers (Basel). 2018 Sep 13;10(9). pii: E326. doi: 10.3390/cancers10090326.

14.

Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Washetine K, Heeke S, Bonnetaud C, Kara-Borni M, Ilié M, Lassalle S, Butori C, Long-Mira E, Marquette CH, Cohen C, Mouroux J, Selva E, Tanga V, Bence C, Félix JM, Gazoppi L, Skhiri T, Gormally E, Boucher P, Clément B, Dagher G, Hofman V, Hofman P.

Cancers (Basel). 2018 Jun 29;10(7). pii: E220. doi: 10.3390/cancers10070220.

15.

Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA.

Washetine K, Kara-Borni M, Heeke S, Bonnetaud C, Félix JM, Ribeyre L, Bence C, Ilié M, Bordone O, Pedro M, Maitre P, Tanga V, Gormally E, Mossuz P, Lorimier P, Marquette CH, Mouroux J, Cohen C, Lassalle S, Long-Mira E, Clément B, Dagher G, Hofman V, Hofman P.

Cancers (Basel). 2018 Jun 11;10(6). pii: E195. doi: 10.3390/cancers10060195.

16.

Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.

Falk AT, Yazbeck N, Guibert N, Chamorey E, Paquet A, Ribeyre L, Bence C, Zahaf K, Leroy S, Marquette CH, Cohen C, Mograbi B, Mazières J, Hofman V, Brest P, Hofman P, Ilié M.

Lung Cancer. 2018 Jul;121:70-75. doi: 10.1016/j.lungcan.2018.05.009. Epub 2018 May 26.

PMID:
29858030
17.

E2F1 inhibition mediates cell death of metastatic melanoma.

Rouaud F, Hamouda-Tekaya N, Cerezo M, Abbe P, Zangari J, Hofman V, Ohanna M, Mograbi B, El-Hachem N, Benfodda Z, Lebeau A, Tulic MK, Hofman P, Bertolotto C, Passeron T, Annicotte JS, Ballotti R, Rocchi S.

Cell Death Dis. 2018 May 1;9(5):527. doi: 10.1038/s41419-018-0566-1.

18.

Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma.

Broncy L, Njima BB, Méjean A, Béroud C, Romdhane KB, Ilie M, Hofman V, Muret J, Hofman P, Bouhamed HC, Paterlini-Bréchot AP.

Oncotarget. 2018 Apr 13;9(28):20058-20074. doi: 10.18632/oncotarget.25102. eCollection 2018 Apr 13.

19.

Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients.

Heeke S, Hofman V, Long-Mira E, Lespinet V, Lalvée S, Bordone O, Ribeyre C, Tanga V, Benzaquen J, Leroy S, Cohen C, Mouroux J, Marquette CH, Ilié M, Hofman P.

Cancers (Basel). 2018 Mar 21;10(4). pii: E88. doi: 10.3390/cancers10040088.

20.

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Hofman V, Lassalle S, Bence C, Long-Mira E, Nahon-Estève S, Heeke S, Lespinet-Fabre V, Butori C, Ilié M, Hofman P.

Cancers (Basel). 2018 Mar 13;10(3). pii: E70. doi: 10.3390/cancers10030070. Review.

Supplemental Content

Loading ...
Support Center